Member of the Association of American Physicians
David E. Moller mainly focuses on Internal medicine, Endocrinology, Peroxisome proliferator-activated receptor, Insulin and Receptor. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Diabetes mellitus. The concepts of his Peroxisome proliferator-activated receptor study are interwoven with issues in Enhancer binding, Transactivation, Peroxisome proliferator-activated receptor delta, Lipid metabolism and Adipogenesis.
His research in Insulin focuses on subjects like Skeletal muscle, which are connected to Glycogen and Gluconeogenesis. In his study, which falls under the umbrella issue of Receptor, PPAR agonist is strongly linked to Nuclear receptor. In Metformin, he works on issues like AMPK, which are connected to Beta oxidation and Carbohydrate metabolism.
His main research concerns Internal medicine, Endocrinology, Insulin, Insulin receptor and Receptor. The Internal medicine study which covers Diabetes mellitus that intersects with Disease. His Endocrinology study frequently intersects with other fields, such as Peroxisome proliferator-activated receptor.
David E. Moller usually deals with Insulin receptor and limits it to topics linked to Insulin-like growth factor 1 receptor and 5-HT5A receptor. His study in Receptor is interdisciplinary in nature, drawing from both Nuclear receptor and Molecular biology. His study focuses on the intersection of Skeletal muscle and fields such as Glucose uptake with connections in the field of Carbohydrate metabolism.
David E. Moller focuses on Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Biochemistry. His Endocrinology research incorporates themes from Peroxisome proliferator-activated receptor and In vivo. His biological study spans a wide range of topics, including Obesity, FGF21, Gastroenterology, Antagonist and Glucagon receptor.
His work on Amino acid, Endoplasmic reticulum, Peroxisome and Receptor as part of his general Biochemistry study is frequently connected to Phosphatidylcholine, thereby bridging the divide between different branches of science. The various areas that David E. Moller examines in his Receptor study include Adipocyte, Cytokine secretion and Peroxisome proliferator-activated receptor alpha. He has included themes like Nicotinamide adenine dinucleotide, NAD+ kinase and Nicotinamide phosphoribosyltransferase in his Insulin study.
The scientist’s investigation covers issues in FGF21, Obesity, Internal medicine, Endocrinology and Adipose tissue. His FGF21 research incorporates elements of Diabetes mellitus, Insulin, Glycemic, Type 2 diabetes and Leptin. His Obesity study combines topics from a wide range of disciplines, such as Lipogenesis and Fatty liver.
His research related to Glucose transporter, Skeletal muscle, Glucose homeostasis, Homeostatic model assessment and Carbohydrate metabolism might be considered part of Internal medicine. His study involves Insulin resistance, Extensor digitorum longus muscle and Glucose uptake, a branch of Endocrinology. His Adipose tissue study combines topics in areas such as Amino acid and Receptor complex.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou;Robert Myers;Ying Li;Yuli Chen.
Journal of Clinical Investigation (2001)
The Mechanisms of Action of PPARs
Joel Berger;David E. Moller.
Annual Review of Medicine (2002)
New drug targets for type 2 diabetes and the metabolic syndrome
David E. Moller.
Fibroblast growth factor 21 corrects obesity in mice.
Tamer Coskun;Holly A. Bina;Michael A. Schneider;James D. Dunbar.
Insulin resistance--mechanisms, syndromes, and implications.
David E. Moller;Jeffrey S. Flier.
The New England Journal of Medicine (1991)
Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
Nicolas Musi;Michael F. Hirshman;Jonas Nygren;Monika Svanfeldt.
Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
David E Moller.
Trends in Endocrinology and Metabolism (2000)
Metabolic syndrome: a clinical and molecular perspective.
David E Moller;Keith D Kaufman.
Annual Review of Medicine (2005)
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich;Jenny Y. Chien;Haoda Fu;Leonard C. Glass.
Cell Metabolism (2013)
Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization
Terry P. Combs;John A. Wagner;Joel Berger;Tom Doebber.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: